Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 17/20 | 0.45 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747359 | 1.00 | TAS2R8 (0.49) | TAS2R8RAF1BRAFLCKKDR | |
| SCHEMBL24401050 | 0.87 | RAF1 (0.63) | RAF1BRAF | |
| SCHEMBL24401048 | 0.78 | RAF1 (0.63) | RAF1BRAF | |
| SCHEMBL24401210 | 0.75 | RAF1 (0.59) | RAF1BRAF | |
| SCHEMBL24401077 | 0.73 | RAF1 (0.47) | RAF1BRAF | |
| SCHEMBL2951528 | 0.69 | LCK (0.56) | TAS2R8BRAFLCKKDRMAPK14 | |
| SCHEMBL30376331 | 0.68 | SMYD3 (0.57) | TAS2R8 | |
| SCHEMBL31120905 | 0.66 | KCNQ3 (0.52) | — | |
| SCHEMBL31095836 | 0.66 | LRRK2 (0.65) | — | |
| SCHEMBL1649415 | 0.66 | TAS2R8 (1.00) | TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | TAS2R8 4621/4885RAF1 3/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.